COVID-19 updates: Elizabeth Warren tests positive

The senator says she's experiencing "mild symptoms."

As the COVID-19 pandemic has swept the globe, more than 5.3 million people have died from the disease worldwide, including over 806,000 Americans, according to real-time data compiled by Johns Hopkins University's Center for Systems Science and Engineering.

About 61.4% of the population in the United States is fully vaccinated against COVID-19, according to data from the Centers for Disease Control and Prevention.


0

US death toll from COVID-19 crosses 800,000

The number of people who have died from COVID-19 in the United States surpassed 800,000 on Tuesday, according to real-time data compiled by Johns Hopkins University's Center for Systems Science and Engineering.

The figure is greater than the approximately 700,000 Americans who have died from AIDS-related illnesses over the last four decades, and it's higher than the total number of U.S. troops who have fallen in battle since 1900.

Since last December, when the first COVID-19 vaccines were being administered, an additional 500,000 people in the U.S. have died from the virus.

Of those, some 230,000 have died since April 2021, when U.S. President Joe Biden announced COVID-19 vaccines were widely available to every American over the age of 18.

-ABC News' Arielle Mitropoulos


US sees sevenfold jump in omicron cases over the last week

The U.S. saw a sevenfold increase in the prevalence of the omicron COVID-19 variant over the last week, according to data from the U.S. Centers for Disease Control and Prevention.

Just over two weeks after it was first discovered in the country, the omicron variant is now estimated to account for nearly 3% of all new cases in the U.S., the latest data from the CDC shows.

Last week, omicron accounted for an estimated 0.4% of all new cases, according to the data.

-ABC News' Arielle Mitropoulos


Omicron will 'for sure' become dominant strain in US: Fauci

Dr. Anthony Fauci told CNN Tuesday that omicron will "for sure" become the dominant strain in the U.S. given how rapidly it is spreading.

"Omicron is going to be a challenge because it spreads very rapidly," Fauci said.

Fauci reiterated that omicron so far appears to be less severe, adding, "Whether it is inherently less pathogenic as a virus or whether there is more protection in the community, we're just going to have to see when it comes in the United States."

-ABC News' Arielle Mitropoulos


Cornell moves exams online due to 'substantial' number of suspected omicron cases

Cornell University is moving into a "level red" alert after a "significant" number of suspected omicron cases were detected among student samples.

"While we must await confirmatory sequencing information to be sure that the source is Omicron, we are proceeding as if it is," university president Martha Pollack wrote in a letter to the community.

All final exams will be online beginning Tuesday, Pollack announced, and libraries and fitness centers are closed.

All undergraduate events are canceled, as is Saturday's recognition ceremony for December graduates, Pollack said.

Cornell has recorded more than 600 confirmed cases among students and staff in the last week alone, according to the university dashboard. While no infected students are seriously sick, Pollack said the university has "a role to play in reducing the spread."

-ABC News' Arielle Mitropoulos, Chris Donato


Vaccine timeline pushed back for kids under 5 

The potential timeline for when children under 5 may have an authorized vaccine is now being pushed back.

Data for a two-shot vaccine was initially expected by the end of the year, but now Pfizer/BioNTech say they hope to have data with a third shot in the first half of 2022.

Pfizer/BioNTech said they "will amend the clinical study evaluating the safety, tolerability, and immunogenicity of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months to under 5 years of age. The study will now include evaluating a third dose of 3 µg at least two months after the second dose of the two-dose series to provide high levels of protection in this young age group."

An early look into the study data suggested that the two doses at a smaller volume was not as effective for kids ages 2 to 5 as it was for the 16 to 25 population, so scientists are going to add a third dose and see if the vaccine is as effective. There were no safety issues reported in the early data analysis.

Pfizer/BioNTech added in a statement, “The decision to evaluate a third dose of 3 µg for children 6 months to under 5 years of age reflects the companies’ commitment to carefully select the right dose to maximize the risk-benefit profile. If the three-dose study is successful, Pfizer and BioNTech expect to submit data to regulators to support an Emergency Use Authorization (EUA) for children 6 months to under 5 years of age in the first half of 2022.”

-ABC News' Eric M. Strauss